Tags : RNAi Therapeutics


Alnylam and Dicerna Collaborate to Develop and Commercialize RNAi Therapeutics

Shots: The collaboration will explore Alnylam’s ALN-AAT02 and Dicerna’s DCR-A1AT, each in P-I/II development for the treatment of alpha-1 liver disease. Dicerna will lead the global clinical development and commercialization (US only) of its DCR-A1AT and Alnylam’s ALN-AAT02 Post P-III completion, Alnylam retains an option to commercialize the selected candidate outside the US. If Alnylam […]Read More

COVID-19 Pharma

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi

Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More